Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)
Conditions
Interventions
Epcoritamab
Locations
3
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Start Date
December 6, 2024
Primary Completion Date
April 30, 2027
Completion Date
December 31, 2027
Last Updated
March 13, 2026
NCT07387471
NCT01804686
NCT02269592
NCT05602363
NCT07231952
NCT04893564
Lead Sponsor
Gottfried von Keudell, MD PhD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions